Alembic Pharmaceuticals Share Price

    NSE
    1000
    -2.30 (0.20%)
    APLLTD • 08 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    2.76%

    3Y Annualised Return

    10.90%

    5Y Annualised Return

    1.23%

    The current prices are delayed, login or Open Demat Account for live prices.

    Alembic Pharmaceuticals Stock Performance

    1W Return1.21
    1Y Return2.76
    Today's Low987.7
    Prev. Close1,002.30
    Mkt Cap (Cr.)19,666.14
    1M Return1.08
    3Y Return36.50
    52-Week High1303.9
    Open996.00
    PE Ratio40.22
    6M Return-5.14
    Today's High1006.6
    52-Week Low725.2
    Face Value2

    Alembic Pharmaceuticals Company background

    Founded in: 2010
    Managing director: Pranav Amin
    Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited. The company is engaged in pharmaceuticals business. As per the Scheme of Arrangement, the Pharmaceutical Undertaking of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with AccuBreak Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA Desvenlafaxine Base Extended Release Tablets and also entered into an outlicensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. During 2014, the company announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary Alembic Global Holding S.A..During 2015, the companys associate signs exclusive agreement with Novartis. During the year, the company launched Aripiprazole on Day1. Also during the year, the company transitioned to own marketing in the US.In 2016, the company formed 60:40 joint venture with Orbicular viz. Aleor Dermaceuitical Limited for developing Dermatology Products for international markets.In July 2017, Alembic Pharmaceuticals inaugurated a state of the art anticancer manufacturing facility at Panelav, Halol, Gujarat. The plant has an initial manufacturing capacity of 60 million tablets/capsules and approximate 20 million vials of liquid injectable and lyophilized concentrates. Alembic will commence exporting oncology products from the new plant to US, Middle East, North Africa, Australia and South Africa. On 1 November 2017, Alembic Pharmaceuticals announced that through its 100% owned subsidiary, Alembic Pharmaceuticals Inc., it has completed acquisition of West Caldwell, New Jersey, USA based generic drug developer Orit Laboratories LLC along with real estate, owned by Okner Realty LLC. Orit has seven approved ANDAs and four ANDAs pending approval. With a stateoftheart 8,600 square feet RD and pilot manufacturing facility, Orit is focused on developing and filing oral solid and liquid products. Apart from existing ANDAs, Orit adds complementary skill sets in soft gelatin based oral solids and oral liquids to Alembic with a team of eight highly experienced scientists. On 21 March 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at the companys formulation facility located at Panelav, Gujarat from 12 March to 20 March 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The company is preparing the response to the observations, which will be submitted to the US FDA shortly. On 24 April 2018, Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Alembic Pharmaceuticals API Facility located at Panelav from 16 April 2018 to 23 April 2018. This was a scheduled inspection and at the end of the inspection, there were zero 483s.In 2019, the Company launched 9 new products in the US.In 2021, Rhizens outlicenced, novel molecule Umbralicib (UKONIQ) was launched by TG Therapeutics USA. During the year 202122, the Company acquired the balance 40% stake held by the joint venture partner in Aleor DermaceuticalsLimited (Aleor) and pursuant to said acquisition, Aleor became a wholly owned subsidiary of the Company.The wholly owned subsidiary, Aleor Dermaceuticals Limited got amalgamated with the Company, making the Scheme of Arrangement effective from 29th August, 2022.During FY23, the Company filed 20 ANDAs and received approvals for 22 ANDAs taking the total filed ANDAs to 245 as on March 31, 2023. At Panelav, Alembic set up dedicated blocks (F2) for manufacturing oncology products which was approved by the US FDA in 2022. The Company launched various new products, especially in the gynecology and antidiabetic spaces it launched 33 new SKUs in FY23, of which 66% were in specialty therapies. It established a subsidiary in Chile to gain a strong foothold in the large and growing Latin American markets. It opened a scientific office in the UAE to capitalise on the opportunities emerging from the GCC nations. Alembic launched 27 new products, including 18 oncology, derma and ophthalmic product in FY24. The Company launched products in speciality and animal health space in FY24. It formed a subsidiary in the UAE by setting up a scientific office during the year.The US Generic business scaled volumes to counter price erosion via strengthening the supply chain in FY 25. It has launched 16 new products, of which 9 OSD, 2 Injectable, 2 Ophthalmic, 3 Dermatology.

    As of 08 Jul, 2025, Alembic Pharmaceuticals share price is ₹1000.5. The stock opened at ₹996 and had closed at ₹1002.3 the previous day. During today’s trading session, Alembic Pharmaceuticals share price moved between ₹987.70 and ₹1,006.60, with an average price for the day of ₹997.15. Over the last 52 weeks, the stock has recorded a low of ₹725.20 and a high of ₹1,303.90. In terms of performance, Alembic Pharmaceuticals share price has declined by 8.3% over the past six months and has increased by 2.76% over the last year.

    Read More
    Alembic Pharmaceuticals SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹65,90,875 (+1.40%)

    Daily SIP of 25,000 would have become 65,90,875 in 1 year with a gain of 90,875 (+1.40%)

    View details of Market Depth

    Alembic Pharmaceuticals Fundamental

    Market Cap (in crs)

    19,666.14

    Face Value

    2

    Turnover (in lacs)

    1,157.68

    Key Metrics

    Qtr Change %
    37.96% Gain from 52W Low
    18.4
    Dividend yield 1yr %
    Above industry Median
    1.1

    Alembic Pharmaceuticals Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Alembic Pharmaceuticals Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    1769.64 Cr
    1692.74 Cr
    1647.98 Cr
    1561.73 Cr
    1516.98 Cr
    Alembic Pharmaceuticals Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    6714.63 Cr
    6256.93 Cr
    5655.36 Cr
    5356.25 Cr
    5403.15 Cr
    4610.69 Cr
    Alembic Pharmaceuticals Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    157.29 Cr
    137.34 Cr
    152.28 Cr
    134.22 Cr
    178.6 Cr
    Alembic Pharmaceuticals Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    581.14 Cr
    616.8 Cr
    372.91 Cr
    515.65 Cr
    1114.76 Cr
    800.65 Cr

    Alembic Pharmaceuticals Result Highlights

    • Alembic Pharmaceuticals Ltd reported a 10.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 8.0%.

    • Its expenses for the quarter were down by 12.3% QoQ and up 4.3% YoY.

    • The net profit increased 29.4% QoQ and increased 16.8% YoY.

    • The earnings per share (EPS) of Alembic Pharmaceuticals Ltd stood at 9.1 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Alembic Pharmaceuticals

    Promoter
    69.7%
    Foreign Institutions
    3.9%
    Mutual Funds
    9.2%
    Domestic Institutions
    16.5%
    Public
    10%
    Promoter
    69.6%
    Foreign Institutions
    4.2%
    Mutual Funds
    9%
    Domestic Institutions
    16%
    Public
    10.2%
    Promoter
    69.6%
    Foreign Institutions
    3.9%
    Mutual Funds
    8.9%
    Domestic Institutions
    16.1%
    Public
    10.4%
    Promoter
    69.6%
    Foreign Institutions
    4.3%
    Mutual Funds
    8%
    Domestic Institutions
    15.5%
    Public
    10.6%
    Promoter
    69.6%
    Foreign Institutions
    4.5%
    Mutual Funds
    7.8%
    Domestic Institutions
    15.3%
    Public
    10.5%
    Promoter
    69.6%
    Foreign Institutions
    4.5%
    Mutual Funds
    7.7%
    Domestic Institutions
    14.5%
    Public
    11.4%

    Alembic Pharmaceuticals Technical Analysis

    Moving Averages Analysis
    1000
    Current Price
    Bullish Moving Averages
    16
    Bearish Moving Averages
    0
    5Day EMA
    1,000.30
    10Day EMA
    994.30
    12Day EMA
    992.20
    20Day EMA
    985.20
    26Day EMA
    980.30
    50Day EMA
    961.50
    100Day EMA
    950.30
    200Day EMA
    958.80
    5Day SMA
    999.90
    10Day SMA
    996.60
    20Day SMA
    980.40
    30Day SMA
    983.20
    50Day SMA
    960.30
    100Day SMA
    903.30
    150Day SMA
    941.70
    200Day SMA
    987.50
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    57914 Rs
    121758 Rs
    Week Rs
    71866 Rs
    266823 Rs
    Month Rs
    119194 Rs
    923243 Rs
    998.27
    Pivot
    Resistance
    First Resistance
    1,008.83
    Second Resistance
    1,017.17
    Third Resistance
    1,027.73
    Support
    First Support
    989.93
    Second support
    979.37
    Third Support
    971.03
    Relative Strength Index
    55.53
    Money Flow Index
    91.57
    MACD
    11.89
    MACD Signal
    10.10
    Average True Range
    33.17
    Average Directional Index
    36.83
    Rate of Change (21)
    1.08
    Rate of Change (125)
    -6.10
    Name
    Holding Percent
    Dsp Midcap Fund
    4.6
    Kotak Small Cap Fund
    1.74
    Life Insurance Corporation Of India
    4.32
    Tata Aia Life Insurance Co Ltd Unit Linked Multi Cap Fund
    1.01

    Alembic Pharmaceuticals Latest News

    08 JUL 2025 | Tuesday

    Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Management

    07 JUL 2025 | Monday

    Alembic Pharmaceuticals Ltd - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    07 JUL 2025 | Monday

    Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Management

    View More

    Alembic Pharmaceuticals Share Price FAQs

    Alembic Pharmaceuticals share price is ₹1000 in NSE and ₹998.6 in BSE as on 8/7/2025.

    Alembic Pharmaceuticals share price in the past 1-year return was 2.75. The Alembic Pharmaceuticals share hit a 1-year low of Rs. 725.2 and a 1-year high of Rs. 1303.9.

    The market cap of Alembic Pharmaceuticals is Rs. 19666.14 Cr. as of 8/7/2025.

    The PE ratios of Alembic Pharmaceuticals is 40.22 as of 8/7/2025.

    The PB ratios of Alembic Pharmaceuticals is 3.78 as of 8/7/2025

    The Mutual Fund Shareholding in Alembic Pharmaceuticals was 9.2% at the end of 8/7/2025.

    You can easily buy Alembic Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Alembic Pharmaceuticals share price is ₹1303.9 and ₹725.2 as of 8/7/2025.

    Please be aware that Alembic Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    66.26
    +0.38 (+0.58%)
    138.20
    -0.34 (-0.25%)
    693.20
    +4.35 (+0.63%)
    2,591.30
    +15.20 (+0.59%)
    166.48
    -0.65 (-0.39%)
    386.50
    -2.95 (-0.76%)
    161.97
    -0.43 (-0.26%)
    263.50
    +4.95 (+1.91%)
    422.00
    +4.90 (+1.17%)
    400.85
    -0.35 (-0.09%)
    Top Gainers
    2,224.50
    +74.70 (+3.47%)
    263.50
    +4.95 (+1.91%)
    2,484.60
    +41.80 (+1.71%)
    343.20
    +5.75 (+1.70%)
    2,820.80
    +41.70 (+1.50%)
    Top Losers
    3,441.30
    -224.80 (-6.13%)
    1,283.80
    -26.70 (-2.04%)
    1,488.30
    -22.20 (-1.47%)
    8,339.50
    -124.00 (-1.47%)
    5,440.00
    -59.00 (-1.07%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -